Article info
Poster Presentations
Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models
SAT0314 A novel highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating fibrosis in preclinical models of systemic sclerosis
Citation
SAT0314 A novel highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating fibrosis in preclinical models of systemic sclerosis
Publication history
- First published June 15, 2017.
Online issue publication
January 09, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions